A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study

Löfström, Björn; Backlin, Carin; Sundström, Christer; Ekbom, Anders; Lundberg, Ingrid E.

doi:10.1136/ard.2006.067108

Cited by 91 publications

(83 citation statements)

References 28 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this definition may increase misclassification; previous nested case-control studies incorporating medical record review of individuals classi- fied as SLE based on a single inpatient visit confirmed half of the sample, at most (3,7). An important caveat is that confirming the diagnosis of SLE by medical record review is complicated and it is unclear what the gold standard should be.…”

Section: Discussionmentioning

confidence: 99%

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Sjöwall

Rönnblom

Jönsen

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Worldwide prevalence estimates of systemic lupus erythematosus (SLE) range from 3 to 207 per 100,000, depending on region and population, SLE definition, case sources, and other methodologic considerations. We aimed to determine the prevalence of SLE in Sweden on January 1, 2010, using population-based registers. Methods. Linking multiple national registers, we identified all possible inpatient and outpatient visits with SLE-specific discharge diagnoses and relevant prescription dispensations among living individuals registered in Sweden on January 1, 2010. SLE was defined from a lenient classification (requiring only a single visit) to stricter definitions that required multiple visits with a history of relevant specialist care and a dispensation for common SLE medications. Prevalence was calculated overall and by sex, age (0 -14 years, 15-49 years, and >50 years, as well as in 5-year age groups), and county of residence. Results. Overall prevalence ranged from 46 per 100,000 for the strictest definition to 85 per 100,000 for the least strict definition. As expected, SLE was more common among females (range 79 -144 per 100,000) than males (range 12-25 per 100,000) and varied by age. The up to 4-fold variation by county was unexpected. Prevalence generally increased with age (2, 52, and 95 per 100,000 by increasing age group, 0 -14 years, 15-49 years, and >50 years, respectively, using a moderately strict definition) and also varied by county. Conclusion. Variations of prevalence by age and sex were consistent with previous studies and overall ranged from 46 to 85 per 100,000. We observed a surprising geographic variation in the prevalence of SLE in Sweden on

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Sjöwall

Rönnblom

Jönsen

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Validation studies using Medicare physician claims data reported 85% sensitivity for SLE claims using the medical record as the gold standard [57,58]. A recent study conducted in Sweden found that 23 of 42 cases identified by administrative data did not have SLE according to their criteria [58].…”

Section: Discussionmentioning

confidence: 99%

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

Parikh‐Patel

White

Allen

et al. 2008

Cancer Causes Control

124

153

View full text Add to dashboard Cite

Objective-We conducted a retrospective cohort study to examine cancer risk in a large cohort of systemic lupus erythematosus (SLE) patients in California.Methods-The cohort consisted of individuals with SLE derived from statewide patient discharge data during the period 1991-2002. SLE patients were followed using cancer registry data to examine patterns of cancer development. Standardized incidence ratios (SlRs) and 95% CI were calculated to compare the observed to expected numbers of cancers based on age-, race-, and sex-specific incidence rates in the California population.Results-The 30,478 SLE patients were observed for 157,969 person-years. A total of 1,273 cancers occurred within the observation interval. Overall cancer risk was significantly elevated (SIR=1.14, 95% CI=1.07-1.20). SLE patients had higher risks of vagina/vulva (SIR=3.27, 95% CI=2.41-4.31) and liver cancers (SIR=2.70, 95% CI=1.54-4.24). Elevated risks of lung, kidney, and thyroid cancers and several hematopoietic malignancies were also observed. Individuals had significantly lower risks of several screenable cancers, including breast, cervix, and prostate.Conclusions-These data suggest that risks of several cancer types are elevated among SLE patients. Detailed studies of endogenous and exogenous factors that drive these associations are needed.The final publication is available at Sprinter via: http://dx

show abstract

“…The pooled analysis combining these data with those of other large cohort studies provided a SIR estimate for HL in SLE of 3.16. Generally, aggressive lymphomas, such as DLBCL are more common in SLE patients , Simon et al, 2007, Bernatsky et al, 2005a, Lofstrom et al, 2007. In general population, DLBCL accounts for 30% of all lymphomas, but in SLE patients this percentage is between 38% and 64% , Bernatsky et al, 2005a, King & Costenbader, 2007.…”

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

“…Some clinical SLE characteristics as haematological manifestations (autoimmune haemolytic anaemia, leukopenia, hyperglobulinemia, chronic thrombocytopenia) (King & Costenbader, 2007), sicca symptoms/salivary gland swellings, pulmonary infiltrates, and/or recurrent pneumonia (Lofstrom et al, 2007) have been associated with increased risk of developing lymphoma. The common involvement of mucosal membranes, salivary glands and lung parenchyma in patients developing a lymphoma could be due to the fact that, in an immune-deficient patient, an impaired barrier for exogenous agents, as viruses, favour recurrent infections, which may be involved in lymphomagenesis.…”

Section: Clinical Characteristicsmentioning

confidence: 99%

“…Diffuse large B cell lymphoma is the most common subtype (King & Costenbader, 2007). After diagnosis of NHL a 5-year survival probability of 47%-50% has been estimated (Bernatsky et al, 2005b, Lofstrom et al, 2007, and mortality in patients with both diseases is usually due to progressive B-cell malignancy (Xu & Wiernik, 2001). …”

Section: Clinical Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Autoimmune Disorders and Lymphomas

Dolcetti¹,

Ponzoni²,

Mappa³

et al. 2011

Autoimmune Disorders - Pathogenetic Aspects

View full text Add to dashboard Cite

A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study

Cited by 91 publications

References 28 publications

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

Autoimmune Disorders and Lymphomas

Contact Info

Product

Resources

About